All In MedTech

Device Trial Radar · NCT06733922

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Exploratory Evaluation of Novel Investigational Eye Movement Biomarkers to Track Ofatumumab Treatment Response in Canadian Patients With Active Relapsing-Remitting Multiple Sclerosis (ELIOS)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

Nov 27, 2024

Primary completion

Mar 31, 2029

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNot on our public-company list
Sponsor type
Industry
First posted
Dec 13, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

Conditions

  • Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions

  • ETNATM-ProgMSDevice

    To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1- Change Eye Movement Biomarkers (EMB)Time frame: 6 months from baseline

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Calgary, Alberta, Canada · Recruiting

15 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.